medigraphic.com
ISSN 2448-8909 (Print)

2024, Number 3

<< Back Next >>

Med Crit 2024; 38 (3)

Risk factors for hospital acquired infection in COVID-19

Moran-Guel E, Gómez-López M, Delgado-Aguirre HA

Language: Spanish
References: 25
Page: 162-168
PDF size: 334.77 Kb.


ABSTRACT

Introduction: patients with COVID-19 have several factors that predispose to coinfections. Mainly, the elevated release of cytokines and deregulation of the immune system. As well as the characteristics of the patient and their comorbidities. Objective: to assess the incidence of coinfection, its pathogens, and the association between the clinical characteristics of patients. Material and methods: a historical cohort study. Patients with COVID-19 admitted to the Intensive Care Unit (ICU) were included, with positive result for SARS-CoV-2 by RT-PCR, cultures were taken on admission. Patients without microbiological reports or who remained < 72 hours in the ICU were excluded. Factors specific to the individual and management in the ICU were studied. The dependent variable was hospital acquired infection (HAI) confirmed by microbiological report. Relative risk (RR) with 95% confidence intervals (95%CI) was calculated. Results: 125 files were studied, 69 (55.2%) were hypertensive, 56 (44.8%) diabetic. We found an incidence of HAI of 39.2% (n = 49) of the study cases. Regarding the frequency of microorganisms isolated, Klebsiella pneumoniae 19 cases (15.2%), followed by E. coli 11 (8.8%), A. baumannii five (4%), two cases (1.6%) from coinfection with Aspergillus spp. The use of tocilizumab presented a RR of 2.13 (95% CI 0.92-4.92) for AHI. Conclusions: in our setting, the AHI of patients with COVID-19 is high, higher than that published by other hospitals. The main germ isolated was Klebsiella pneumoniae. No clinical factors associated with HAI were found.


REFERENCES

  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.

  2. Kim L, Garg S, O'Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2021;72(9):e206-e214.

  3. Tuty Kuswardhani RA, Henrina J, Pranata R, Anthonius Lim M, Lawrensia S, Suastika K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(6):2103-2109. doi: 10.1016/j.dsx.2020.10.022.

  4. García-Alvarado FJ, Muñoz-Hernández MA, Moran Guel E, González-Martínez MDR, Macías Corral MA, Delgado-Aguirre HA. Risk factors and clinical phenotypes associated with severity in patients with COVID-19 in Northeast Mexico. Vector Borne Zoonotic Dis. 2021;21(9):720-726. doi: 10.1089/vbz.2021.0016.

  5. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS One. 2021;16(5):e0251170. doi: 10.1371/journal.pone.0251170.

  6. Fernandes-Matano L, Monroy-Muñoz IE, Uribe-Noguez LA, et al. Coinfecciones por SARS-CoV-2 y su desenlace clínico. Rev Med Inst Mex Seguro Soc. 2021;59(6):482-489.

  7. Nebreda-Mayoral T, Miguel-Gómez MA, March-Rosselló GA, et al. Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y León, Spain. Enferm Infecc Microbiol Clin (Engl Ed). 2020;40(4):158-165. doi: 10.1016/j.eimc.2020.11.003.

  8. Despotovic A, Milosevic B, Cirkovic A, et al. The impact of COVID-19 on the profile of hospital-acquired infections in Adult Intensive Care Units. Antibiotics (Basel). 2021;10(10):1146. doi: 10.3390/antibiotics10101146.

  9. Colli-Cortés MB. Algoritmo de tratamiento COVID-19 centrado en identificación temprana de factores de riesgo. Rev Med Inst Mex Seguro Soc. 2020;58 Supl 2:S301-308. doi: 10.24875/RMIMSS.M20000142.

  10. Mucito-Varela E, Osorio-Juárez RA, Rosales-Reyes R, Jiménez-Hernández LE. Patología clínica, diagnóstico y tratamiento en la infección por SARS-CoV-2. Rev Med Inst Mex Seguro Soc. 2020;58(Supl 2):S292-S300. doi: 10.24875/RMIMSS.M20000141.

  11. Olvera-Reyes O, Abrego-Lara JH. Terapias específicas propuestas para el manejo de COVID-19. Rev Med Inst Mex Seguro Soc. 2020;58(2):229-237. doi: 10.24875/RMIMSS.M20000134.

  12. Talavera JO, Roy-García I, Palacios-Cruz L, Rivas-Ruiz R, Hoyo I, Pérez-Rodríguez M. De vuelta a la clínica. Métodos I. Diseños de investigación. Mayor calidad de información, mayor certeza a la respuesta. Gac Med Mex. 2019;155(4):399-405. doi: 10.24875/gmm.19005226.

  13. Li Q, Wang Y, Sun Q, et al. Immune response in COVID-19: what is next? Cell Death Differ. 2022;29(6):1107-1122. doi: 10.1038/s41418-022-01015-x.

  14. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454. doi: 10.1038/s41418-020-0530-3.

  15. Wang B. Risk factor analysis and nomogram construction for non-survivors among critical patients with COVID-19. Jpn J Infect Dis. 2020;73:452-458.

  16. Chong WH, Saha BK, Ananthakrishnan R, Chopra A. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. Infection. 2021;49(4):591-605. doi: 10.1007/s15010-021-01602-z.

  17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

  18. Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808-810. doi: 10.1016/j.cmi.2020.04.024.

  19. Kubin CJ, McConville TH, Dietz D, et al. Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections. Open Forum Infect Dis. 2021;8(6):ofab201. doi: 10.1093/ofid/ofab201.

  20. Cabrera CE, Gómez RF, Zuñiga AE, Corral RH, López B, Chávez M. Epidemiology of nosocomial bacteria resistant to antimicrobials. Colomb Med. 2011;42(1):117-125.

  21. Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis. 2021;72(10):e533-e541. doi: 10.1093/cid/ciaa1239.

  22. Vazquez-Guillamet C, Scolari M, Zilberberg MD, Shorr AF, Micek ST, Kollef M. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock. Crit Care Med. 2014;42(11):2342-2349. doi: 10.1097/CCM.0000000000000516.

  23. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459-2468. doi: 10.1093/cid/ciaa530.

  24. Stanevich OV, Fomina DS, Bakulin IG, et al. Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study. BMC Infect Dis. 2021;21(1):1277. doi: 10.1186/s12879-021-06982-z.

  25. Plata-Menchaca EP, Ferrer R. Procalcitonin is useful for antibiotic deescalation in sepsis. Crit Care Med. 2021;49(4):693-696. doi: 10.1097/CCM.0000000000004776.




2020     |     www.medigraphic.com